Clinical Focus

  • Emergency Medicine

Academic Appointments

Professional Education

  • Board Certification: American Board of Lifestyle Medicine, Lifestyle Medicine (2022)
  • Board Certification: American Board of Integrative Holistic Medicine, Integrative Medicine (2018)
  • Fellowship: University of Arizona Center for Integrative Medicine (2015) AZ
  • Board Certification: American Board of Emergency Medicine, Emergency Medicine (1997)
  • Residency: John H Stroger Hospital of Cook County Emergency Medicine Residency (1996) IL
  • Residency: Mount Sinai Hospital Dept of Neurosurgery (1992) NY
  • Internship: Mount Sinai School of Medicine (1991) NY
  • Medical Education: Icahn School of Medicine at Mount Sinai (1990) NY

Contact

  • Academic
    laugro@stanford.edu
    University - Academic staff Department: Med/Primary Care and Population Health Position: Clinical Assistant Professor
  • Clinical (Primary)  Stanford Internal Medicine 211 Quarry Rd Rm 302 3rd Fl Palo Alto, CA 94304 (408) 750-0006 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5411

All Publications

  • Post-COVID-19 Vaccination and Long COVID: Insights from Patient-Reported Data. Vaccines Quach, T. C., Miglis, M. G., Tian, L., Bonilla, H., Yang, P. C., Grossman, L., Paleru, A., Xin, V., Tiwari, A., Shafer, R. W., Geng, L. N. 2024; 12 (12)

    Abstract

    COVID-19 vaccinations reduce the severity and number of symptoms for acute SARS-CoV-2 infections and may reduce the risk of developing Long COVID, also known as post-acute sequelae of SARS-CoV-2 (PASC). Limited and heterogenous data exist on how these vaccinations received after COVID-19 infection might impact the symptoms and trajectory of PASC, once persistent symptoms have developed.We investigated the association of post-COVID-19 vaccination with any SARS-CoV-2 vaccine(s) on PASC symptoms in two independent cohorts: a retrospective chart review of self-reported data from patients (n = 128) with PASC seen in the Stanford PASC Clinic between May 2021 and May 2022 and a 2023 multinational survey assessment of individuals with PASC (n = 484).Within the PASC Clinic patient cohort (n = 128), 58.6% (n = 75) were female, and 41.4% (n = 53) were male; 50% (n = 64) were white, and 38.3% (n = 49) were non-white. A total of 60.2% (n = 77) of PASC Clinic patients reported no change in their PASC symptoms after vaccination, 17.2% (n = 22) reported improved symptoms, and 22.7% (n = 29) reported worsened symptoms. In the multinational survey cohort (n = 484), 380 were from the U.S., and 104 were from outside the U.S.; 88.4% (n = 428) were female, and 11.6% (n = 56) were male; and 88.8% (n = 430) were white, and 11.2% (n = 54) were non-white. The distribution of survey self-reported vaccine effects on PASC symptoms was 20.2% worsened (n = 98), 60.5% no effect (n = 293), and 19.2% improved (n = 93). In both cohorts, demographic features, including age, sex, and race/ethnicity, were not significantly associated with post-vaccination PASC symptom changes. There was also a non-significant difference in the median dates of COVID-19 infection among the different outcomes. BMI was significant for symptom improvement (p = 0.026) in the PASC Clinic cohort, while a history of booster doses was significant for symptom improvement (p < 0.001) in the survey cohort.Most individuals with PASC did not report significant changes in their overall PASC symptoms following COVID-19 vaccinations received after PASC onset. Further research is needed to better understand the relationship between COVID-19 vaccinations and PASC.

    View details for DOI 10.3390/vaccines12121427

    View details for PubMedID 39772087